Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

Stopped early · Phase 4

Conditions studied: Pulmonary Hypertension

In brief

Inhaled Iloprost will be administered to near term infants with Persistent Pulmonary Hypertension of the Newborn in two different doses in order to test safety and efficacy in reducing pulmonary artery pressure.

Key facts

Study ID

NCT00409526

Run by

University of Chicago

People needed

1

Starts

2006-12-01

Expected to finish

2007-12-01

Last updated by the study team

2014-06-02

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Near-term infants (>34 gestational age) with evidence of persistent pulmonary hypertension and severe hypoxia(PaO2<100 mmHg with mechanical ventilation with FiO2=100%).

You may not qualify if…

• Major congenital malformation
• Congenital diaphragmatic hernia
• Structural cardiac anomalies
• Hydrops fetalis
• Pulmonary hemorrhage
• Severe perinatal depression
• Patients on high frequency oscillation ventilator

Where it is running

• Comer Children's Hospital, The University of Chicago Hospitals — Chicago, Illinois, United States
• Shaare Zedek Medical Center — Jerusalem, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.